Ibrance (chemical name: palbociclib) has been granted accelerated approval by the U.S. Food and Drug Administration to be used in combination with the hormonal therapy Femara (chemical name: letrozole) to treat locally advanced-stage or metastatic, estrogen-receptor-positive, HER2-negative breast cancer that hasn’t been treated with hormonal therapy before in postmenopausal women.
In this section you can learn more about:
- How Ibrance Works
- Will Ibrance Work for You?
- What to Expect When Taking Ibrance
- Ibrance Side Effects